Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New directions in hematologic biotherapy.

J E Groopman1

  • 1Department of Medicine, New England Deaconess Hospital, Boston, MA 02215.

Seminars in Hematology
|July 1, 1989
PubMed
Summary

Recombinant biologic agents like interferons and erythropoietin offer new treatments for blood, cancer, and heart diseases. However, high costs necessitate collaboration to ensure patient access to these vital therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

British journal of pharmacology·2010
Same author

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.

Oncogene·2009
Same author

Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.

Oncogene·2007
Same author

Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.

Oncogene·2007
Same author

Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration.

The Journal of biological chemistry·2001
Same author

HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation.

Journal of immunology (Baltimore, Md. : 1950)·2001

Area of Science:

  • Biotechnology and Medicine
  • Pharmacology
  • Oncology

Background:

  • Recombinant biologic agents represent a significant advancement in treating various disorders.
  • Key agents include interferons, recombinant human erythropoietin (r-HuEPO), colony-stimulating factors (CSFs), interleukins (ILs), and tissue plasminogen activator (t-PA).

Purpose of the Study:

  • To review the therapeutic applications of recombinant biologic agents in hematologic, oncologic, and cardiologic disorders.
  • To highlight the efficacy of specific agents in various conditions.
  • To address the challenges of high treatment costs and the need for collaborative solutions.

Main Methods:

  • Review of clinical trial data and therapeutic outcomes for recombinant biologic agents.
  • Analysis of specific applications in hematologic malignancies, solid tumors, anemia, neutropenia, and myocardial infarction.
  • Discussion of economic factors influencing treatment accessibility.

Main Results:

  • Interferon alfa shows efficacy in hematologic malignancies, solid tumors, and AIDS-related Kaposi's sarcoma.
  • r-HuEPO effectively treats anemia in hemodialysis patients.
  • CSFs (G-CSF, GM-CSF) improve outcomes post-bone marrow transplant and in various neutropenic conditions.
  • t-PA demonstrates superior efficacy over streptokinase in myocardial infarction.
  • High development and testing costs lead to expensive treatments.

Conclusions:

  • Recombinant biologic agents offer substantial therapeutic benefits across multiple medical fields.
  • The high cost of these advanced therapies presents a significant barrier to access.
  • Multistakeholder collaboration is crucial to ensure financial accessibility for patients needing these life-saving treatments.

Related Experiment Videos